Gülen and Zhou Weiwen, buy these pharmaceutical and gold stocks in the first quarter!
Every reporter: Huang Xiaocong Every editor: Zhao Yun
The fund's quarterly report continued to be disclosed, and the holdings of more well-known fund managers surfaced.
The reporter of "Daily Economic News" noticed that the CEIBS Medical and Health Care managed by the CEIBS Fund Gülen reduced its holdings in the first quarter, and the new top 10 was Dong'e Ejiao, while the CEIBS Medical Innovation reduced its holdings of Hengrui Pharmaceutical, Aier Ophthalmology, WuXi Biologics and other stocks, and Gushengtang entered the top 10.
In addition, Zhou Weiwen of China Europe Fund, which manages China Europe New Blue Chip and China Europe New Trend, reduced his holdings of Wen's shares and other stocks in the first quarter, and bought stocks such as Zijin Mining in heavy positions.
Gülen: Reduced holdings of Gloria Eng and WuXi Biologics, and bought Dong'e Ejiao and Gushengtang
Wind data shows that as of the end of the first quarter of this year, the cumulative scale of the three products managed by China Europe Fund Gülen was about 45.9 billion yuan, down from 57.3 billion yuan at the end of last year.
In terms of holdings, CEIBS Healthcare mainly reduced its holdings in Aier Ophthalmology, Pien Tze Huang, Tong Ren Tang and other stocks in the first quarter, and slightly increased its position in WuXi AppTec.
In addition, Kailaiying withdrew from the top ten, and the new entry is Dong'e Ejiao.
At the end of last year, Dong'e Ejiao's shareholding was only 11.8235 million shares, and as of the end of the first quarter of this year, it had increased to 21.508 million shares.
Looking at the medical innovation of CEIBS, in the first quarter, it mainly reduced its holdings of stocks such as Hengrui Pharmaceutical and Aier Ophthalmology, and WuXi Biologics withdrew from the top 10, and the new top 10 was Gushengtang.
Looking ahead to the second quarter, Gülen said: "We remain optimistic about the innovation-driven pharmaceutical industry chain. Overseas, although the pace of interest rate cuts in 2024 is still uncertain, the trend of relatively loose overall liquidity is confirmed. Domestically, the policy continues to strengthen support for innovation in the field of medicine and biology. As an important part of new quality productivity, pharmaceutical innovation is also the firmest direction of enterprise layout. In 2023, the number of varieties of chemical drugs, biological drugs, and traditional Chinese medicine innovative drugs applying for marketing will continue to increase, and 2024 is expected to usher in the peak period of approval and marketing of related innovative drugs. “
"Of course, we also see that the development of the domestic innovative drug industry chain is facing certain twists and turns. The healthy and sustainable development of the industrial chain requires unified coordination from corporate financing, product project approval, R&D promotion, registration application, entry into the hospital procurement catalog, compliance sales, medical insurance payment, etc. In view of the pain points of each link of the industrial chain, in recent years, the national level has also continued to carry out scientific coordination and precise dredging through policies and measures, and the overall guidance direction of the industrial chain is still real innovation, which is mainly reflected in new targets, new mechanisms, new structures, new technologies and drugs with independent intellectual property rights, as well as effective treatment methods to solve clinical needs. It is foreseeable that the support and guidance of national policies are expected to drive a new round of healthier and more sustainable R&D cycles, which also contain opportunities worthy of layout in advance. ”
In addition, Gülen said: "We are also actively concerned about the progress of the competitive medical industry chain going overseas. With the continuous advancement of the internationalization level of the medical device field, some enterprises have gradually made international breakthroughs in the field of high value chain and occupied overseas market opportunities, mainly focusing on innovative equipment, in vitro diagnostics and other fields. Although the internationalization process of some enterprises will be affected by the phased changes in the global geopolitical situation, the long-term core competitiveness of high-quality assets in the domestic innovation industry chain has not changed. ”
Zhou Weiwen: Reduced his holdings of Wen's shares and bought Zijin Mining
At present, Zhou Weiwen of CEIBS Fund has managed a total of 5 funds, with a cumulative management scale of about 33.4 billion yuan, of which the management time of CEIBS New Blue Chip Blend and CEIBS New Trend Blend is the longest, both of which have exceeded 12 years.
Let's focus on the changes in the holdings of these two funds. First of all, in the first quarter, the new blue-chip mixed between China and Europe mainly reduced its holdings of stocks such as Kweichow Moutai and Spring Airlines, and increased its positions in stocks such as Wanhua Chemical and Zhongji Innolight.
In addition, a more obvious change is that Wen's shares, Desay SV, and Huatai Securities have all withdrawn from the top 10, and the new entrants are Zijin Mining, COSCO Marine Energy and Tongce Medical.
In the first quarter, the new trend of Central Europe mainly reduced its holdings of individual stocks such as Kweichow Moutai and Spring Airlines.
Added positions in Wanhua Chemical, Zhongji Innolight, Lixun Precision and other stocks.
In addition, Wen's shares withdrew from the top 10, and the new entry was Zijin Mining.
Overall, Zhou Weiwen's first quarterly report mainly increased the allocation of computing power related to the AI industry chain, downstream application companies, and upstream resources that benefit from the physical cycle and liquidity cycle.
In addition, Zhou Weiwen said in a quarterly report: "The performance of the high-dividend sector is better because in the context of low interest rates and high-quality growth, dividend yield has become an important consideration for the underlying asset allocation of some long-term institutions." The good performance of the AI industry is due to the breakthrough of the newly released model and the application of Wensheng video, and the market's expectation of the progress of the development of the AI industry is therefore advanced, and the related targets of AI video and AI applications are sought after by the market. Gold, copper and other non-ferrous metals performed well, due to the combined effect of factors such as the expectation of US interest rate cuts and supply constraints. ”
National Business Daily